Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2014Journal of Clinical OncologyOpen Access

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJosep‐María RiberaAOAlbert OriolMMMireia Morgades

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ribera et al. (2014) studied this question.

synapsesocial.com/papers/6a94653b4ec1eb7af13edd2fhttps://doi.org/10.1200/jco.2013.52.2425
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study2008 · 143 citations
  2. 2Modern Therapy of Acute Lymphoblastic Leukemia2011 · 489 citations
  3. 3Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis2012 · 133 citations
  4. 4Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG29932009 · 152 citations
  5. 5Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia2005 · 539 citations